| المؤلفون: |
Dunn KPR; Cumming School of Medicine Indigenous, Local and Global Health Office, Calgary, AB, Canada; Indigenous Wellness Core, Alberta Health Services, Calgary, AB, Canada., Oster RT; Indigenous Wellness Core, Alberta Health Services, Calgary, AB, Canada., Williams KP; Indigenous Wellness Core, Alberta Health Services, Calgary, AB, Canada., Egan CE; Indigenous Wellness Core, Alberta Health Services, Calgary, AB, Canada., Letendre A; Public Health Evidence & Innovation, Alberta Health Services, Calgary, AB, Canada; Alberta Cancer Prevention Legacy Fund, Calgary, AB, Canada., Crowshoe H; Piikani First Nation, Brocket, AB, Canada., Potestio ML; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada., Lee SS; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: samlee@ucalgary.ca. |
| مستخلص: |
Competing Interests: SSL has consulted for AbbVie, Gilead Sciences, Justice Canada (HCV file). All other authors declared no competing interests. We express gratitude to the communities across Alberta who have collaborated in the ECHO programme, as well as the advisory committee in shaping and supporting this collaborative approach. We acknowledge the ECHO programme is located on Treaty 6, 7, and 8, and on Métis Nation of Alberta Region 3 lands. KPRD, KPW, AL, and HC are Indigenous peoples. Total HCV treatment data for Alberta were kindly provided by IQVIA (Kirkland, QC, Canada). |
